AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Another Major Accomplishment for Dune Medical as it Launches its First In-Man Trial for its Revolutionary Smart Biopsy Device

March 26, 2019
The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 738529. (Graphic: Business Wire)

ALPHARETTA, Ga.--(BUSINESS WIRE)--Mar 26, 2019--Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy device which leverages the real-time tissue characterization capability of its radio-frequency (RF) spectroscopy technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005346/en/

The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 738529. (Graphic: Business Wire)

These first in-man cases were completed by Dr. Noemi Weissenberg, Radiologist, at the Meir Medical Center in Kfar Saba, Israel. Utilizing miniaturized sensors located on a core needle, Smart Biopsy generated, in real time, electrical parameters of the sampled tissue. These electrical parameters will be compared to histopathologic findings in order to provide additional value with regard to improving diagnosis and read-out.

The Smart Biopsy device represents a significant breakthrough in Dune Medical’s quest to offer real-time, multi-cancer, diagnostic and treatment applications. Dune Medical’s RF Spectroscopy and its miniaturized sensor technology provide the most accurate interpretation of electrical parameters which correlate to tissue type, and most importantly, to the differentiation between cancer and healthy tissue. Identifying tissue properties during the biopsy procedure enables the physician to enhance their diagnostic capability beyond just image guidance, potentially preventing patients the anxiety of an underdiagnosis or an overdiagnosis. The Smart Biopsy Device and its technology were recently featured in an article by Medical Device and Diagnostic Industry (MD+DI).

The development of the Smart Biopsy Device was supported by the prestigious European Union Horizon 2020 research grant that Dune Medical received in 2016.

Dune Medical Devices CEO Lori Chmura is enthusiastic about the progress made. “The in-man phase is the continuation of a broader and more comprehensive clinical trial aimed at definitive tissue characterization in the breast, Dunes first application. The collective works will be published later this year as a revolutionary solution for enhancing accuracy in biopsy diagnosis and guide future development of RF Spectroscopy across the oncology spectrum. We’re thrilled to have met this important milestone in our strategy to offer multi-cancer applications.”

About Dune Medical Devices
“Imagine not having to wonder, did we get it all?”
At Dune Medical Devices, we believe in reducing the anxiety that waiting for pathology results places on a patient and their families. Our solutions, which are developed on a first-of-its-kind RF Spectroscopy platform, can differentiate cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question, “did we get it all?” For more information, contact info@dunemedical.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005346/en/

CONTACT: Write2Market for Dune Medical Devices

Jean-Luc Vanhulst

jl@write2market.com

+1 (347) 453-7686

KEYWORD: UNITED STATES NORTH AMERICA GEORGIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY RADIOLOGY RESEARCH SCIENCE

SOURCE: Dune Medical Devices

Copyright Business Wire 2019.

PUB: 03/26/2019 08:00 AM/DISC: 03/26/2019 08:00 AM

http://www.businesswire.com/news/home/20190326005346/en